To test this hypothesis, a siRNA targeting BECN1, which reduces the expression of BECN1 in CRC cells (Supplementary Figures S4A, B), or Tat-BECN1 (Tat), a BECN1 activator, was used to treat HMGB1-depleted CRC cells. This evidence concerns the gene TAT and colorectal carcinoma.